International Patent: HER3 TARGETED RADIOTHERAPY FOR THE TREATMENT OF RELAPSED AND OR REFRACTORY SOLID TUMORS

GENEVA, Aug. 21 -- ACTINIUM PHARMACEUTICALS, INC. filed a patent application (US2026/014939) for “HER3 TARGETED RADIOTHERAPY FOR THE TREATMENT OF RELAPSED AND OR REFRACTORY SOLID TUMORS”. With publication no. WO/2026/173993, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: A61K 51/10

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....